CD274 and mesothelioma: The efficacy of the combination of cisplatin/pemetrexed and the anti-programmed cell death ligand-1 (PD-L1) antibody Durvalumab has been investigated in mesothelioma patients in the multicenter, single-arm, phase II DREAM clinical trial [24].